Acorda Therapeutics Hits Ch. 11, Plans $185M Drug Sale

By Yun Park · April 2, 2024, 11:29 AM EDT

Neurological disorders drugmaker Acorda Therapeutics Inc. filed for Chapter 11 protection in New York bankruptcy court, with plans to sell its assets to another pharmaceutical company for $185 million....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

Acorda Therapeutics, Inc.

Case Number

Court

New York Southern

Nature of Suit

Date Filed

April 01, 2024

Recent Articles By Yun

March 06, 2024
Rite Aid Aims To Divest Most Of Its Health Dialog Business
February 02, 2024
Drugmaker Endo Wants To Extend Opioid Suit Pause
January 16, 2024
24 Hour Fitness Asks To Keep COVID Coverage Claims Alive
December 06, 2023
Air Methods Gets OK For $1.7B Ch. 11 Plan
December 04, 2023
GenesisCare Lender Objects To DIP Refinancing Move
December 04, 2023
Pear Therapeutics Seeks WARN Act Class Suit Settlement
November 27, 2023
US Trustee Balks At MedStaff Firm's Bass Berry Retention
November 20, 2023
Dermatology Drug Developer Hits Ch. 11 With Sale Plan
November 14, 2023
SmileDirectClub Investors Say Ch. 11 Releases Are Too Broad
November 03, 2023
SmileDirect Creditors Want $55M DIP Delayed For Exec Probe